IMCIVREE delivered early, significant, and sustained reduction in BMI Z-score1
Change in BMI Z-score from baseline in patients <18 years of age after 52 weeks (n=14)1

86%
achieved a clinically significant ≥0.2 reduction* in BMI Z-score1,2
- 100% of patients <12 years of age (n=3) achieved a clinically significant ≥0.2 reduction in BMI Z-score
*A clinically significant reduction is generally considered a ≥0.2 reduction in BMI Z-score. A 0.2 reduction is comparable to weight loss of approximately 5%.2
IMCIVREE significantly reduced the severity of obesity due to BBS1

This chart is a visual representation of what a female child with BBS* who started IMCIVREE at 12 years of age may experience in BMI reduction after 52 weeks, based on data from the phase 3 trial.1-5

*Not an actual patient.
Growth chart is based on females 2 to 20 years of age and is for illustrative purposes only.